Literature DB >> 18482681

Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the "glucose-corrected" SUV.

Mohiuddin Hadi1, Stephen L Bacharach, Millie Whatley, Steven K Libutti, Stephen E Straus, V Koneti Rao, Robert Wesley, Jorge A Carrasquillo.   

Abstract

INTRODUCTION: 2-Deoxy-2[(18)F]fluoro-d-glucose (FDG) positron emission tomography (PET) has an established role in the evaluation of cancer. Generally, tumor uptake and response to treatment are evaluated using the standardized uptake value (SUV). Some authors have proposed correcting SUV for glucose levels. Insulin is also thought to influence tumor uptake by changing uptake in other tissues. However, little attention has been paid to understanding the variability of glucose or insulin during a single PET study.
METHOD: We studied the biological and instrumental variability of glucose and insulin measurements in 71 nondiabetic patients undergoing FDG-PET studies. Multiple glucose measurements were obtained in all 71 subjects, and in 69 of these 71 subjects, multiple serum insulin measurements were made. We determined the coefficient of observed variation (CV(ow)) and the coefficient of variation attributable to biological variability (CV(bv)) for both glucose and insulin.
RESULTS: The mean glucose concentration was 78.9+/-13.5 mg/dl. The mean insulin value was 6.49+/-5.92 microU/ml. The weighted mean CV(ow) and CV(bv) was 5.0% and 3.6%, respectively, for glucose and 14.2% and 8.3%, respectively, for insulin.
CONCLUSIONS: Variations in the range of 3.6% are observed in glucose measurements during the time course of an FDG scan even after accounting for analytical error; larger variations of 8.3% are observed in insulin levels. Therefore, corrections of SUV for blood glucose, especially if obtained from single measurements, can introduce additional errors of at least this much.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18482681     DOI: 10.1016/j.nucmedbio.2008.02.007

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  6 in total

1.  Glucose-corrected standardized uptake value (SUVgluc) is the most accurate SUV parameter for evaluation of pulmonary nodules.

Authors:  Amin Haghighat Jahromi; Farshad Moradi; Carl K Hoh
Journal:  Am J Nucl Med Mol Imaging       Date:  2019-10-15

2.  (124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo.

Authors:  Mikhail Doubrovin; Tatiana Kochetkova; Elmer Santos; Darren R Veach; Peter Smith-Jones; Nagavarakishore Pillarsetty; Julius Balatoni; William Bornmann; Juri Gelovani; Steven M Larson
Journal:  J Nucl Med       Date:  2010-01       Impact factor: 10.057

3.  Total-body PET/CT using half-dose FDG and compared with conventional PET/CT using full-dose FDG in lung cancer.

Authors:  Hui Tan; Xiuli Sui; Hongyan Yin; Haojun Yu; Yusen Gu; Shuguang Chen; Pengcheng Hu; Wujian Mao; Hongcheng Shi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-11-27       Impact factor: 9.236

4.  Impact of noninsulin-dependent type 2 diabetes on carotid wall 18F-fluorodeoxyglucose positron emission tomography uptake.

Authors:  Jan Bucerius; Venkatesh Mani; Colin Moncrieff; James H F Rudd; Josef Machac; Valentin Fuster; Michael E Farkouh; Zahi A Fayad
Journal:  J Am Coll Cardiol       Date:  2012-06-05       Impact factor: 24.094

5.  The power of FDG-PET to detect treatment effects is increased by glucose correction using a Michaelis constant.

Authors:  Simon-Peter Williams; Judith E Flores-Mercado; Andreas R Baudy; Ruediger E Port; Thomas Bengtsson
Journal:  EJNMMI Res       Date:  2012-06-27       Impact factor: 3.138

6.  Factors affecting tumor (18) F-FDG uptake in longitudinal mouse PET studies.

Authors:  Wei Sha; Hu Ye; Keisuke S Iwamoto; Koon-Pong Wong; Moses Quinn Wilks; David Stout; William McBride; Sung-Cheng Huang
Journal:  EJNMMI Res       Date:  2013-07-10       Impact factor: 3.138

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.